Study on the Therapeutic Effect of TCM Treatment for MDR MN
NCT ID: NCT02610595
Last Updated: 2015-11-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
220 participants
INTERVENTIONAL
2015-12-31
2016-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
experimental group
Jianpixiaozhong particles and Wuse Dietotherapy
Jianpixiaozhong particles and Wuse Dietotherapy
Jianpixiaozhong particles: Three packs once,bid po; Wuse Dietotherapy: one packs once,bid po
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Jianpixiaozhong particles and Wuse Dietotherapy
Jianpixiaozhong particles: Three packs once,bid po; Wuse Dietotherapy: one packs once,bid po
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Gender, nationality;
3. Pixushuifan syndrome, IMN confirmed by renal biopsy and clinical examination;
4. Treatment invalided by two or more than two kinds of Hormone or immunosuppressive agents ;
5. CKD phase 1-3（eGFR（EPI Formula）≥30ml/min/1.73m2）
Exclusion Criteria
2. Anti-nuclear antibodies, double stranded DNA, ANCA or other indicators of immune disorders;
3. Active hepatitis B and liver function test sustained abnormal;
4. Patients with malignant tumor or have a history of cancer, HIV infection, history of mental illness, acute central nervous system diseases, severe gastrointestinal diseases;
5. Merger with other serious disease and dysfunction of the organ;
6. Gravid or lactation woman;
7. Other clinical trials are being studied.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fudan University
OTHER
Ruijin Hospital
OTHER
Shanghai 6th People's Hospital
OTHER
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
OTHER
Changhai Hospital
OTHER
Shanghai Putuo District Center Hospital
OTHER
ShuGuang Hospital
OTHER
Shanghai Yueyang Integrated Medicine Hospital
OTHER
Shanghai Changzheng Hospital
OTHER
Shanghai Minhang Central Hospital
OTHER
Zhujiang Hospital
OTHER
Guangxi Traditional Chinese Medical University
OTHER
Huashan Hospital
OTHER
The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine
OTHER
Xinqiao Hospital of Chongqing
OTHER
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
OTHER
Nanjing University of Traditional Chinese Medicine
OTHER
Tongji Hospital
OTHER
Chinese Academy of Sciences
OTHER_GOV
RenJi Hospital
OTHER
Shanghai University of Traditional Chinese Medicine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Nephrology,Longhua Hospital
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ZY3-CCCX-3-2001
Identifier Type: -
Identifier Source: org_study_id